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A number of statistical models have been successfully developed
for the analysis of high-throughput data from a single source, but
few methods are available for integrating data from different sources.
Here we focus on integrating gene expression levels with comparative
genomic hybridization (CGH) array measurements collected on the
same subjects. We specify a measurement error model that relates the
gene expression levels to latent copy number states which, in turn, are
related to the observed surrogate CGH measurements via a hidden
Markov model. We employ selection priors that exploit the depen-
dencies across adjacent copy number states and investigate MCMC
stochastic search techniques for posterior inference. Our approach
results in a unified modeling framework for simultaneously inferring
copy number variants (CNV) and identifying their significant associ-
ations with mRNA transcripts abundance. We show performance on
simulated data and illustrate an application to data from a genomic
study on human cancer cell lines.
1. Introduction. Our understanding of cancer biology and the mecha-
nisms underlying cancer cell growth has progressed tremendously over the
past decade. Cancer is the consequence of a dynamic interplay at different
molecular levels (DNA, mRNA and protein). Elucidating the association
between two or more of these levels would enable the identification of bi-
ological relationships that could lead to improvements in cancer diagnosis
and treatment. Consequently, studies that integrate different types of high-
throughput data are of great interest. This paper is concerned with the
integration of gene expression and copy number variant data.
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Gene expression levels correspond to the relative abundance of mRNA
transcripts. These expression levels can be altered by chromosomal aber-
rations, such as copy number variants (CNV). CNVs are variations in the
copy number of DNA segments due to cytogenetic events, in which the
DNA replication process is disrupted and the DNA segment is either repli-
cated (once or several times) or deleted in newly generated cells, leading
to local chromosomal amplifications/deletions [Sebat et al. (2004)]. Several
experimental techniques are available for CNV detection. The most widely
used high-throughput technologies include comparative genomic hybridiza-
tion (CGH) arrays and single nucleotide polymorphism (SNP) arrays. In this
paper, we focus on the former, which generates data as reads on thousands
or millions of genomic hybridization targets (probes) spotted on a glass
surface. Regions of relative gains or losses are identified by measuring the
fluorescence ratio of differentially labeled test and reference DNA samples
hybridized onto the array. The reference DNA is assumed to have two copies
of each chromosome. If the test sample has no copy number aberrations, the
log2 of the intensity ratio is theoretically equal to zero.
A number of statistical methods have been developed to infer CNVs from
high-throughput array-based technologies. The most widely used rely on
hidden Markov models (HMM) [Colella et al. (2007), Wang et al. (2007)]
and circular binary segmentation [Venkatraman and Olshen (2007)]. Other
methods based on clustering have been proposed, including a combination
of segmentation and model-based clustering [Picard et al. (2007)] and a
Bayesian hierarchical mixture model [Cardin and Holmes (2011)]. These
methods process each sample one at a time and require post-processing of
the inferred CNV calls to resolve CNV boundary variations.
In addition to CNV detection, there is often interest in identifying vari-
ants associated with specific phenotypes or biological functions. Most of the
available methods either directly use the normalized continuous intensity
measurements without inferring copy numbers or use the estimated copy
numbers as true states, then assess the associations using univariate tests
or by performing simple linear regression models with multiple testing cor-
rection [Stranger et al. (2007), Wang et al. (2007)]. When using the raw
measurements, the aggregation of a large number of tests with low p-values
in close genetic proximity is considered evidence of copy number-phenotype
association. Although this approach has the advantage of circumventing the
need to infer copy number, the high noise in the signal intensities leads to
the identification of a large number of false positives [Breheny et al. (2012)].
On the other hand, using the copy number calls as if they were the true
states ignores the uncertainty in the estimation process and can introduce
bias. Several methods have been proposed to incorporate the uncertainty
in copy number estimation into the association tests [Barnes et al. (2008),
Subirana et al. (2011)].
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In the past few years, there has been a growing interest in relating gene
expression and CNV data. Indeed, locating CNVs that affect gene dosage
is an important step in understanding biological processes underlying var-
ious diseases. In cancer, for example, where chromosomal aberrations are
widespread due to genomic instability, discovering amplification of onco-
genes or deletion of tumor suppressors are important steps in elucidating
tumorigenesis. Earlier attempts in this area have used Pearson correlation
coefficients to evaluate associations between raw CGH intensities and gene
expression levels mapping to the same genomic region [Bussey et al. (2006),
Chin et al. (2006)]. Choi, Qin and Ghosh (2010) developed a double-layered
mixture model to simultaneously estimate copy numbers and evaluate the
association between each copy number probability score and the expression
level of the corresponding gene. These models perform univariate associa-
tions between CNVs and gene expression levels on the same chromosomal
region. However, it would be expected that multiple CNVs mapping to dif-
ferent genomic regions may be associated to gene regulation, a mechanism
that is part of epistasis; see Cordell (2002).
Several multivariate statistical methods for integrating genomic data sets
have been proposed in recent years. Monni and Tadesse (2009) proposed
a stochastic partitioning method to identify sets of correlated gene expres-
sion levels and select sets of chromosomal abberations that jointly modulate
mRNA transcript abundance in the co-expressed genes. Other authors have
proposed variable selection methods in multivariate linear regression models
in the context of eQTL (expression quantitative trait loci) analysis. Among
those, Richardson, Bottolo and Rosenthal (2010) proposed mixture priors
that enforce sparsity while enhancing the detection of predictors that are
associated with many responses. Similar priors have also been studied by
Scott-Boyer et al. (2012) for eQTL analysis.
In this paper we develop an innovative statistical model that integrates
gene expression and copy number variant data. The proposed approach pro-
vides a unified framework to simultaneously infer CNVs across all samples
and identify significant associations between copy number states and gene
expression changes. To achieve this goal, we first specify a joint distribution
of the observed gene expression and CGH data across all samples. Using a
measurement error model formulation, we factor this joint distribution into
the product of conditionally independent submodels: an outcome model that
relates the gene expression levels to latent copy number states, and a mea-
surement model that relates these latent states to the observed surrogate
CGH measurements using a first order hidden Markov model (HMM). We
identify CNVs associated with gene expression changes by incorporating a
latent indicator for variable selection into the outcome model and specify-
ing selection priors that account for spatial dependences between adjacent
DNA segments. Our strategy for posterior inference uses MCMC algorithms
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Fig. 1. Graphical formulation of the probabilistic model described in Section 2.
and stochastic search methods and results in the estimation of copy number
states across all samples, as well as the selection of groups of CNVs associ-
ated with gene expression. The model we propose allows the identification
of the joint effect of multiple CNVs on mRNA transcript abundance, rather
than assuming univariate associations. In addition, the simultaneous evalua-
tion of multiple gene expression levels reduces the detection of false positive
associations by borrowing information across co-expressed genes. We show
the performance of our proposed model on simulated data. We also analyze
a case study on human cancer cell lines. Findings support the hypothesis
that our approach has the potential to discover important linkages between
gene expression and cancer.
The rest of the paper is organized as follows: Section 2 introduces the
modeling framework and its major components and Section 3 describes the
posterior inference and prediction. Results on simulated data are reported
in Section 4, while Section 5 is devoted to our case study. Section 6 contains
some final remarks.
2. Hierarchical model. We propose a hierarchical model that integrates
gene expression levels with copy number variant data and that accounts
for the measurement error in the observed CGH intensities via a hidden
Markov model (HMM). The model further incorporates a variable selec-
tion procedure and utilizes prior distributions that exploit the dependencies
across adjacent DNA segments. Our modeling strategy provides a unified
approach for simultaneously inferring copy number states for all samples
and identifying associations between sets of copy number variants and gene
expression levels. The graphical formulation of the model is illustrated in
Figure 1 and its major components are described below. We also summarize
the hierarchical formulation of our full model in Figure 2.
Let Yig denote the expression measurement for gene g (g = 1, . . . ,G) and
Xim the observed CGH measurement, that is, the normalized log2 ratio,
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Likelihood:
f(Z|ξ) =
n∏
i=1
{
G∏
g=1
f(Yig|ξi)
M∏
m=1
f(Xim|ξim)
}
,
f(Yig|ξ) =N(µg + ξiβg, σ
2
g),
f(Xim|(ξim = j)) =N(ηj, σ
2
j ),
P (ξi(m+1) = h|ξim = j) = ahj .
Model parameters:
βgm|rgm, σ
2
g ∼ rgmN(0, c
−1
β σ
2
g) + (1− rgm)δ0(βgm),
µg|σ
2
g ∼N(0, c
−1
µ σ
2
g),
σ−2g ∼Ga(δ/2, d/2),
ηj ∼N(δj , τj)I{lowηj<ηj<uppηj}
,
σ−2j ∼Ga(bj , lj)I{σ−2
j
>uppσj }
,
ah ∼Dir(φ).
Variable selection parameters:
pi(rgm|rg(m−1), rg(m+1),ξ, pi1)
= γm[pi
rgm
1 (1− pi1)
(1−rgm)] +
2∑
j=1
ω(j)m I{rgm=rg(m+(−1)j )},
pi1 ∼ Beta(e, f).
Fixed hyperparameters: cµ, cβ , δ, d, e, f,α,δ,τ ,b, l,φ, lowη,uppη,uppσ
Fig. 2. Hierarchical formulation of the proposed probabilistic model.
for the mth CGH probe (m= 1, . . . ,M ), in sample i (i = 1, . . . , n). We as-
sume the M CGH probes ordered according to their chromosomal location
and refer to probes m and m + 1 as adjacent. In our modeling approach
we treat the observed CGH intensities, Xim, as surrogates for unobserved
copy number states, which we indicate with ξim. Failure to account for the
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measurement error, by treating the surrogates as the latent copy number
states, may lead to biased results. Here we define four copy number states
corresponding to the following:
ξim = 1 for copy number loss (less than two copies of the fragment);
ξim = 2 for copy-neutral state (exactly two copies of the fragment);
ξim = 3 for a single copy gain (exactly three copies of the fragment);
ξim = 4 for multiple copy gains (more than three copies of the fragment).
Let Z= [Y,X] denote the (n× (G+M)) matrix of observed gene expres-
sion measurements and let ξ = [ξ1, . . . ,ξM ] be the (n×M) matrix of latent
copy number states. We consider a nondifferential measurement error, which
assumes that, conditional on the latent state ξ, the observed surrogate X
contains no additional information on the responseY [Richardson and Gilks
(1993)], that is, f(Y|ξ,X) = f(Y|ξ). The joint distribution of Z can thus be
decomposed into conditionally independent submodels, that correspond to
an outcome model relating Y to the latent state ξ and a measurement model
relating the surrogate X to ξ, as f(Z|ξ) = f(Y|ξ)f(X|ξ). We further assume
conditional independence of the gene expression measurements, given the
copy number states (i.e., Yi ⊥Yj |ξ1, . . . ,ξM ) and conditional independence
of the CGH measurements, given their states (i.e., Xi ⊥Xj |ξ1, . . . ,ξM ), and
write
f(Z|ξ) =
n∏
i=1
{
G∏
g=1
f(Yig|ξi)
M∏
m=1
f(Xim|ξim)
}
.(1)
Even though we make these assumptions, we still borrow strength across
genes via our hierarchical prior specification, as described in Section 2.2.
2.1. Measurement error model via HMM. For the outcome model in (1)
we follow Monni and Tadesse (2009) and Richardson, Bottolo and Rosen-
thal (2010) who have suggested linear regression models that integrate gene
expression levels with genetic data. For gene g we therefore specify a linear
regression model of the type
Yig = µg + ξiβg + εig, i= 1, . . . , n(2)
for g = 1, . . . ,G and with µ1, . . . , µG gene-specific intercepts. We also assume
εig ∼N(0, σ
2
g) with σ
2
g a gene specific variance.
We then define the measurement model in (1) in terms of the emission
probabilities of a Hidden Markov Model (HMM). CGH data are “state per-
sistent,” meaning that copy number gains or losses at a region are often
associated to an increased probability of gains and losses at a neighboring
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region. Here, we adapt the model proposed by Guha, Li and Neuberg (2008),
that uses hidden Markov models with four copy number states. Methods
that consider the number of possible states as a random variable, such as
those of Fox et al. (2011), Du et al. (2010) and Costa et al. (2013), may be
similarly incorporated into our model. Conditional on the latent copy num-
ber states, we assume the observed CGH measurements independent and
normally distributed, defining the emission distributions of the HMM as
Xim|(ξim = j)
i.i.d.
∼ N(ηj , σ
2
j ),(3)
with ηj and σ
2
j representing the expected log2 ratio and the variance of all
CGH probes in state j (j = 1, . . . ,4). The dependence between the states
at adjacent probes is captured by a first order Markov model, which as-
sumes that the probability of being in a particular copy number state at
chromosomal location m+ 1 depends only on the state at location m,
P (ξi(m+1)|ξi1, . . . , ξim) = P (ξi(m+1)|ξim) = aξimξi(m+1) ,
with A = (ahj) forming the matrix of transition probabilities with strictly
positive elements (h, j = 1, . . . ,4). This matrix has a unique stationary dis-
tribution piA. The initial probabilities of being in each of the states at m= 1
are also assumed to be given by piA.
2.2. Prior models for spatial dependence. For each gene we wish to find
a parsimonious set of CGH aberrations that affect the gene expression levels
with high confidence. This is equivalent to inferring which elements of the
vector βg in (2) are nonzero, that is, a classical variable selection problem.
The resulting “network” of gene-CGH associations can be encoded by a
(G×M ) matrix R of binary elements. Specifically, for gene expression g and
CGH probem, the value rgm = 1 indicates that the corresponding coefficient
βgm is significant, and should therefore be included in the regression model
for gene g. Otherwise, rgm = 0 indicates that the corresponding regression
coefficient is zero. Given R, the regression coefficient parameters are then
stochastically independent and have the following mixture prior distribution:
pi(βgm|rgm, σ
2
g) = rgmN(0, c
−1
β σ
2
g) + (1− rgm)δ0(βgm),(4)
with δ0(·) a point mass at zero and cβ > 0 a hyperparameter to be chosen
(see Section 4). The prior model is completed with a Gamma prior on the
error precision, σ−2g ∼G(
δ
2 ,
d
2), and a Normal distribution on the intercepts,
µg|σ
2
g ∼N(0, c
−1
µ σ
2
g), with δ, d and cµ hyperparameters to be chosen.
Priors of type (4) are known as spike-and-slab priors in the Bayesian vari-
able selection literature [see George and McCulloch (1997) for linear regres-
sion models and Brown, Vannucci and Fearn (1998) and Sha et al. (2004) for
multivariate models] and have been employed to infer biological networks
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of high dimensionality [see, e.g., Jones et al. (2005), Richardson, Bottolo
and Rosenthal (2010) and Stingo et al. (2010)]. We adopt the formulation of
Stingo et al. (2010) which allows to select different covariates (CNV aber-
rations) for different responses (genes). See also Monni and Tadesse (2009)
for an approach based on partition models.
We now describe our prior choice for the elements rgm’s of this matrix
R that encodes the association network. Since contiguous regions of copy
number changes correspond to the same DNA aberration, they are more
likely to jointly affect the expression level of a gene. Accordingly, in our prior
distribution we explicitly assume that the probability of selection at location
m depends on the copy number states and the selection of the probes at
positions {m− 1,m+1}. Hence, CNVs located in regions of persistent state
aberrations may be more likely to be jointly associated with the expression
levels of each gene. We represent this dependent association structure as a
conditional mixture prior distribution
pi(rgm|rg(m−1), rg(m+1),ξ, pi1) = γm[pi
rgm
1 (1− pi1)
(1−rgm)]
(5)
+
2∑
j=1
ω(j)m I{rgm=rg(m+(−1)j)},
where γm ∈ [0,1] and
∑2
j=1ω
(j)
m = (1− γm). According to (5), with proba-
bility γm, we have that rgm ∼ Bern(pi1), independently of the neighboring
values, whereas, with probability (1− γm), rgm coincides with either one (or
both) of the adjacent values in R. We note that equation (5) reduces to the
typical independence assumption, rgm ∼Bern(pi1), in the case γm = 1.
In this paper we assume that the parameters γm, ω
(1)
m and ω
(2)
m are probe-
specific, capturing information on the physical distance between CGH probes
and their unobserved copy number states. More specifically, let dm be the
distance between the adjacent probes {m − 1,m} and let D be the total
length of the DNA fragment (e.g., the length of the chromosome) under
consideration. We define
1− s(m−1)m = 1−
1
n
n∑
i=1
e{1−dm/D} − 1
e− 1
I{ξim=ξi(m−1)}(6)
to capture the frequency of change points at position m in copy number
states across all samples. Similar quantities have been used, for example, by
Wang et al. (2008, 2007) and Marioni, Thorne and Tavare (2006), to model
spatial dependency in copy number detection. Here, instead, we use them to
elicit the association between each gene expression and stretches of CNVs in
the following sense. If two CGH probes are physically close, state persistence
might be more likely and the same association pattern would be expected
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compared to a situation where the two probes are located farther apart on
the genome. Accordingly, we define
γm =
α
α+ s(m−1)m + sm(m+1)
,
(7)
ω(1)m =
s(m−1)m
α+ s(m−1)m + sm(m+1)
, ω(2)m =
sm(m+1)
α+ s(m−1)m + sm(m+1)
with α set to a positive real value. In the applications we set ω
(1)
m and ω
(2)
m
to zero for the first and last chromosomal locations, that is, m = 1 and
m=M . We note that, if s(m−1)m = sm(m+1) = 0, equation (5) reduces to the
independent case, whereas larger values of either s(m−1)m or sm(m+1) imply
smaller γm and, respectively, larger ω
(1)
m or ω
(2)
m , that is, stronger spatial
dependency. The prior probability of rgm = 1 therefore increases if rg(m−1)
[or rg(m+1)] is equal to one and if there are more samples with no change
between the copy number states at locations m andm−1 (orm+1). Finally,
we complete prior (5) by further imposing a Beta hyperprior, pi1 ∼Beta(e, f).
Integrating pi1 out, we obtain
pi(rgm|rg(m−1), rg(m+1),ξ) = γm
Γ(e+ f)Γ(e+ rgm)Γ(f +1− rgm)
Γ(e+ f +1)Γ(e)Γ(f)
(8)
+
2∑
j=1
ω(j)m I{rgm=rg(m+(−1)j )}.
It is immediate to show that this prior is proper since it is nonnegative and
has finite support.
As for the prior specification of the HMM of equation (3), we assume inde-
pendent Dirichlet priors across the rows of the transition matrix A, that is,
ah = (ah1, ah2, ah3, ah4)∼Dir(φ1, φ2, φ3, φ4), for h= 1, . . . ,4. For ηj and σ
2
j in
the emission distributions (3) we follow Guha, Li and Neuberg (2008) and as-
sume ηj ∼N(δj , τ
2
j )I{lowηj<ηj<uppηj }
and σ−2j ∼Gamma(bj , lj)I{σ−2j >uppσj }
,
for j = 1, . . . ,4. Here lowη1 =−∞, uppη4 =∞, while all other hyperparam-
eters are defined by the user on the base of the platform (see Section 4).
Figure 2 summarizes the full hierarchical formulation of our model.
2.3. Choice of the α parameter. The parameter α in (7) captures the
relative strength of the dependence. In particular, α= 0 implies γm = 0 (for
m = 1, . . . ,M ), whereas α→∞ leads to γm = 1, that is, the independent
prior. In our applications, we found that a poor choice of α can have un-
desirable effects on the prior probability. To elucidate this further, let us
arbitrarily fix s(m−1)m = sm(m+1) = 0.65. Figure 3 shows plots of the prior
probabilities (5) for a grid of values of α in [1,100], for pi1 = 0.001 and
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Fig. 3. Effect of α on the prior probabilities of inclusion (5) for (a) pi1 = 0.001 and (b)
pi1 = 0.1.
pi1 = 0.1. These plots show that strong dependence assumptions, that is, rel-
atively low values of α, may have a differential effect on the probabilities, at
the expense of model sparsity. We notice also that the effect of α is stronger
when the probability of success of the Bernoulli prior is lower. We discuss
sensitivity to α in the simulation studies below.
3. Posterior inference. Our primary interest lies in the estimation of the
association matrix R and the matrix of copy number states ξ. Given that
the posterior distribution is not available in closed form, we design a Markov
chain Monte Carlo algorithm, based on stochastic search variable selection
algorithms. Once we integrate out µ, βg and σ
2
g , the marginal likelihood
reduces to
f(Yg|ξ,R) =
(2pi)−n/2(cµ/(cµ + n))
1/2(cβ)
kg/2Γ((n+ δ)/2)(d/2)δ/2
|Ug|1/2Γ(δ/2)((d+ qg)/2)((n+δ)/2)
,(9)
where qg =Y
′
gHnYg −Y
′
gHnξRU
−1
g ξ
′
RHnYg, Ug = cβIkg + ξ
′
RHnξR and
Hn = In −
1n1
′
n
n+cµ
, with kg indicating the number of selected regressors for
the gth regression function. We give full details of our MCMC algorithm in
the supplementary material [Cassese et al. (2014)]. The updates at a generic
iteration can be described as follows:
• Update R via a Metropolis step. We first select ng genes at random using
a geometric distribution with parameter pR. Then, for each selected gene,
with probability ρ we choose between an Add/Delete or Swap move; for
the Add/Delete move we select at random one of the elements in the
corresponding row of R and change its value (from 0 to 1, or vice versa);
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for the Swap move we select two elements with different inclusion status
and swap their values. In updating R, we do not consider CGH probes
called in copy neutral state in more than n× pMC samples at the current
MCMC iteration (with pMC set by the user), since these would not be
expected to be associated with changes in mRNA transcript abundance.
The proposed move is then accepted with probability
min
[
f(Y|ξ,Rnew)pi(Rnew|ξ)
f(Y|ξ,Rold)pi(Rold|ξ)
,1
]
.
Since all moves are symmetric, the proposal distribution does not appear
in the previous ratio.
• Update ξ via a Metropolis step. This step consists of choosing at random
a column of ξ, say, m, and updating the values of nm of its elements,
selected at random using a geometric distribution with parameter pξ. For
each element, a candidate state is sampled using the current transition
matrix A [i.e., we propose ξnewim based on ξ
old
i(m−1)] and the proposal is
accepted with probability
min
[
f(Y|ξnew,R)f(X|ξnew)pi(R|ξnew)pi(ξnew|ξold,A)q(ξold|ξnew)
f(Y|ξold,R)f(X|ξold)pi(R|ξold)pi(ξold|ξold,A)q(ξnew|ξold)
,1
]
.
• Update ηj , for j = 1, . . . ,4, via a Gibbs step. We sample ηj|X,ξ, σj ∼
N(νj , θ
−2
j )I{lowηj<ηj<uppηj}
, with precisions θj = τ
−2
j +njσ
−2
j and weighted
means νj = θ
−2
j (δjτ
−2
j + X¯jnjσ
−2
j ), with nj =
∑M
m=1
∑n
i=1 I{ξim=j} and
X¯j =
1
nj
∑M
m=1
∑n
i=1XimI{ξim=j}.
• Update σj , for j = 1, . . . ,4, via a Gibbs step. We sample σj|X,ξ, ηj ∼
IG(bj+
nj
2 , lj+
Vj
2 )I{σ−2j >uppσj }
, where nj =
∑M
m=1
∑n
i=1 I{ξim=j} and Vj =
(Xim − ηj)
2I{ξim=j}.
• Update A via a Metropolis step. We generate a new vector for each row
of A as Anew.j |ξ ∼ Dir(φ1 + oh1, φ2 + oh2, φ3 + oh3, φ4 + oh4), where ohj =∑n
i=1
∑M−1
m=1 I{ξim=h,ξi(m+1)=j}, and accept it with probability
min
[
1,
n∏
i=1
piAnew(ξi1)
piAold(ξi1)
]
.
Given the MCMC output, we first perform inference on R by calculating
the marginal posterior probability of inclusion (PPI) for each element, esti-
mated by counting the number of iterations that element was set to 1, after
burn-in. A selection is then made by looking at those elements of R that
have marginal PPI greater than a value that guarantees an expected rate
of false detection (Bayesian FDR) smaller than a fixed threshold, which we
set at 0.05. We follow Newton et al. (2004) and calculate the Bayesian FDR
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as FDRB(k) =
∑
g
∑
m(1−PPI gm)Ik∑
g
∑
m Ik
, where k is the threshold on the PPI and
Ik is an indicator function such that Ik = 1 if (1 − PPI gm) ≤ k. We then
estimate ξ by calculating, for each position, the most frequent state value.
The MCMC output also allows us to make inference on the HMM param-
eters, that is, the transition matrix A and the means and variances of the
emission distributions in (3).
4. Simulation studies. We study the performance of our model on a set
of simulated scenarios. The normal human genome is diploid. However, re-
cent studies have reported that as much as 12% of the human genome is
variable in copy numbers [Redon et al. (2006)]. When copy number changes
occur, they affect segments of DNA, so neighboring chromosomal regions
are expected to have similar copy numbers. Furthermore, transitions from
copy number variants to the diploid state are expected to be more likely than
transitions between different copy number variants (e.g., from one-copy dele-
tion to one-copy duplication). Taking those considerations into account, we
generated a synthetic n×M matrix of copy numbers, ξ, as follows:
• We initialized the matrix ξ with all elements set to 2.
• We randomly selected L <M columns (including some stretches of ad-
jacent columns) and generated their values using the following transition
matrix: 

0.7500 0.1800 0.0500 0.020
0.4955 0.0020 0.4955 0.007
0.0200 0.1800 0.7000 0.010
0.0001 0.3028 0.1000 0.597

 .
• We randomly selected additional M−L2 columns. For each column, we gen-
erated 10% of its values according to the transition matrix above.
Following Guha, Li and Neuberg (2008), we sampled the copy number state
for the first CGH probe from the initial probability vector piA, obtained
as the normalized left eigenvector associated with the eigenvalue 1. Given
the resulting states, we generated the matrix X as in (3), where we fixed
η1 = −0.65, η2 = 0, η3 = 0.65, η4 = 1.5 and σ1 = 0.1, σ2 = 0.1, σ3 = 0.1, σ4 =
0.2. We simulated the association network R as follows. First we set all the
M − L columns equal to 0. From the remaining columns we selected a to-
tal of l elements and set those to 1. We set all the remaining elements to
0. We then generated the regression coefficients corresponding to the l se-
lected associations by sampling from normal distributions, as β ∼N(β0, σ
2
0),
where β0, σ0 were fixed as detailed in the next sections and the signs were
assigned randomly. Finally, we generated the gene expression outcomes, Yig
(g = 1, . . . ,G) as Yig = µg + ξiβg + εig with µg ∼N(0, σ
2
µg ), σµg = 0.1, and
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Table 1
Simulation study: Specification of the HMM hyperparameters
HMM parameters State 1 State 2 State 3 State 4
δj −1 0 0.58 1
τj 1 1 1 2
lowηj −∞ −0.1 0.1 η3 + σ3
uppηj −0.1 0.1 0.73 ∞
uppσj 0.41 0.41 0.41 1
εig ∼N(0, σ
2
ε ). Unless otherwise specified, in the following we set n = 100,
G= 100, M = 1000, L= 250, l = 20 and σε = 0.1. We also considered sim-
ulated scenarios with a different σε value for each gene g and found similar
performances to those we report below [Cassese et al. (2014)].
As for hyperparameter settings, those in (4) and (5) determine the amount
of shrinkage in the model. We followed the guidelines provided by Sha et al.
(2004) and chose cβ in the range of variability of the data so as to control
the ratio of prior to posterior precision. Specifically, we set cβ = 10, in all
simulations. Furthermore, we specified vague priors on the intercept term,
by setting cµ = 10
−6, and on the error variance σ2g , by setting δ = 3 and
choosing d such that the expected value of σ2g represents a fraction of the
observed variance of the standardized responses (5% for the results reported
here). For all scenarios, we considered the dependent prior model (8) with
e= 0.001 and f = 0.999 and assessed sensitivity for varying α in (7) in the set
{5,10,50,100,∞}. The notation α=∞ succinctly indicates the independent
prior. For the HMM model, similar to Guha, Li and Neuberg (2008), we set
ηj ∼ N(δj , τ
2
j ) · I{lowηj<ηj<uppηj}
, σ−2j ∼ Ga(bj , lj) · I{σ<uppσj}
with bj = 1,
lj = 1, j = 1, . . . ,4, and the other hyperparameters specified as in Table 1.
The lower bound for η4, lowη4 was set to avoid that a large number of
single copy gains be erroneously classified as multiple copy gains. The choice
of the truncation σ−2j > 6 is a mild assumption, and it is equivalent to
setting σj < 0.41. Finally, we assumed each row of the transition matrix as
independently distributed according to Dir(1,1,1,1).
When running the MCMC chains, we sampled initial values for ηj and
σj from their respective priors and initialized ξ as ξim = j (j = 1, . . . ,4) if
Xim > Tj with T= [−∞,−0.5,0.29,0.79]. We derived the initial value of A
from the initial ξ, based on the proportion of transitions. We set the initial
R as a matrix with all elements equal to zero. All results reported here
were obtained with MCMC chains with 500,000 iterations and a burn-in
of 350,000, fixing pR = 0.4, pξ = 0.6, pMC = 0.9 and ρ = 0.5. We assessed
convergence by inspecting the MCMC sample traces for all parameters; see
Figure 4 for an example of typical plots. Moreover, we applied the diagnostic
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Fig. 4. Simulation study: Trace plots for: (a) R, number of ones in the association ma-
trix, (b) ξ4, number of positions estimated as multiple gains, (c) η4, mean value of the
positions estimated as multiple gains and (d) σ4, standard deviation of the positions esti-
mated as multiple gains, for one MCMC run on simulated scenario 1. We note that state
four has the smallest number of observations, thus, more variance and less stationarity is
expected.
test of Geweke (1992) for the equality of the means, based on the first 10%
and the last 50% of the chain. We also used the Heidelberger and Welch
(1981) test on the stationarity of the distribution to determine a suitable
burn-in.
4.1. Inference on the association network (R). We present results from
two simulated scenarios. The first scenario assumes no particular (spatial)
dependence structure in the association between markers and genes. For this
scenario, we generated l regression coefficients as β ∼N(2,0.32), except for 6
values which we drew from N(0.5,0.32), to take into account a lower signal to
noise ratio. In the second scenario we explicitly assumed dependence among
the regression coefficients. In particular, we selected two clusters of adjacent
CGH probes and assumed they affect the expression of the same gene. The
corresponding coefficients were sampled as β ∼N(0.5,0.32). In both scenar-
ios, we simulated data for two values of the error standard deviation, that
is, σε = 0.1 and σε = 0.5.
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Fig. 5. Simulated data: Simulated scenario 1 with σε = 0.1: Marginal posterior proba-
bilities of inclusion of the elements rgm of the association matrix R. Plots refer to prior
model (8) with (a) α = 20, (b) α = 100, (c) α =∞ (independent prior). Vertical lines
indicate the true gene-CNVs associations.
We start by analyzing the results for the first scenario. Figure 5 shows
marginal PPIs of the elements rgm of R, for the case σε = 0.1. The model
recovers well the true gene-CNVs associations (vertical lines), although it is
evident that relatively small values of α, implying greater a priori depen-
dence structure, result in an increased number of erroneous decisions when
such structure is indeed not present in the data. A selection of the significant
associations is made by considering those elements of R that have marginal
PPI greater than a value that guarantees a prespecified FDR. For example,
the first panel of Table 2 reports results in terms of specificity, sensitivity,
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Table 2
Simulated scenarios 1 and 2: Results on specificity, sensitivity, false positives, false
negatives, number of detections and Bayesian q-values, for the dependent prior model (8)
and the independent case (α=∞), obtained for an FDR threshold of 0.05
α= 5 α= 10 α = 20 α= 30 α= 40 α= 50 α= 100 α=∞
Scenario 1 σε = 0.1
Spec. 0.99785 0.99795 0.99999 1 0.99999 0.99999 1 1
Sens. 0.95 0.95 0.9 0.95 0.9 0.9 0.9 0.8
FP/FN 215/1 205/1 1/2 0/1 1/2 1/2 0/2 0/4
# detect 234 224 19 19 19 19 18 16
q-value 0.048679 0.046491 0.03444 0.042294 0.045403 0.048651 0.024107 0.024674
σε = 0.5
Spec. 0.99999 0.99999 0.99999 1 1 1 0.99999 0.99999
Sens. 0.95 0.95 0.9 0.9 0.9 0.85 0.8 0.8
FP/FN 10/1 1/1 1/2 0/2 0/2 0/3 1/4 1/4
# detect 29 20 19 18 18 17 17 17
q-value 0.046464 0.041118 0.049538 0.038603 0.0428 0.026924 0.028897 0.033866
Scenario 2 σε = 0.1
Spec. 0.99987 0.99998 0.99999 0.99999 0.99999 0.99999 0.99999 0.99999
Sens. 0.95 0.95 0.95 0.95 0.95 0.95 0.9 0.85
FP/FN 13/1 2/1 1/1 1/1 1/1 1/1 1/2 1/3
# detect 32 21 20 20 20 20 19 18
q-value 0.045476 0.0452311 0.031514 0.042635 0.044119 0.046781 0.04567 0.035927
σε = 0.5
Spec. 0.99989 0.99994 0.99998 0.99998 0.99998 0.99998 0.99998 0.99998
Sens. 0.85 0.85 0.85 0.8 0.8 0.8 0.7 0.6
FP/FN 11/3 6/3 2/3 2/4 2/4 2/4 2/6 2/8
# detect 28 23 19 18 18 18 16 14
q-value 0.04506 0.049371 0.039412 0.041290 0.045759 0.047261 0.047235 0.047865
false positives (FP), false negatives (FN) and number of detections, obtained
with an upper bound on the FDR set to.05. Sensitivity is calculated as the
ratio of true positive (TP) counts over l and specificity as the ratio of true
negatives (TN) over (G ×M − l). In the same table we also report the
realized Bayesian q-value, calculated as min{(1−PPI )≤k}FDRB(k); see, for
example, Broet et al. (2004) and Morris et al. (2008). Results show that a
lower α leads to less FN calls but increased FP counts. However, due to the
large number of TNs, such effect translates in much improved sensitivity at
the expense of only a minimal decrease in specificity. Results are similar for
σε = 0.5, although, as expected, the model performance improves when the
error variance is smaller (see lower panel of each scenario in Table 2).
In order to investigate the effect of the threshold on the PPIs on the
selection results, in Figure 6(a) we report ROC-type curves displaying FP
counts versus FN counts calculated at a grid of equispaced thresholds in the
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Fig. 6. Simulated scenarios 1 (a) and 2 (b) with σε = 0.1: Numbers of FP and FN ob-
tained by considering different thresholds on the marginal probabilities of inclusion of Fig-
ure 5. Threshold values are calculated as a grid of equispaced points in the range [0.07,1].
Plots refer to prior model (8) with different values of α.
interval [0.07,1]. The plots clearly show that dependent priors obtained for
lower values of α generally outperform the independent case, regardless of
the threshold.
Our results are confirmed by the second simulated scenario. As expected,
dependent priors improve the FP counts (see the last two panels of Table 2),
since the spatial dependence in the gene-CNVs association structure is now
explicitly taken into account. Indeed, the independent prior shows worse
performance, due to its inability to use information gathered from adjacent
probes. As in the first simulated scenario, we again notice that lower values of
α lead to less FN calls but increased FP counts; see Table 2 and Figure 6(b).
As a general guideline regarding the choice of this parameter, our results
indicate that moderate values of α give an appropriate compromise between
false positives and false negatives. See Section 6 for additional discussion.
4.2. Inference on the CNV states (ξ) and the HMM parameters. We now
turn to the inference on the CGH states, encoded by the matrix ξ. Table 3
reports the misclassification counts and corresponding percent rates. In order
to compute these summary statistics, for each element we considered the
modal state attained at each genomic location over all MCMC iterations
(after burn-in). The misclassification rates appear to be consistent over the
different values of α and of the error standard deviation σε. A close look
at the distribution of the misclassifications over the four states showed that
most errors occur between adjacent classes (results not shown).
Our model allows also to conduct inference on the parameters of the
HMM, that is, the transition matrix A and the means and variances of the
18 A. CASSESE ET AL.
emission distributions in model (3). As an example, scenario 1 (σε = 0.1) us-
ing the independent prior gave the following estimates: ηˆ = [−0.64963,0.00044,
0.64936,1.50717] and σˆ = [0.10206,0.09994,0.10069,0.21187], which appear
to be all very close to the simulated values, with the exception of σ4 which
is slightly overestimated. This is the standard deviation of the amplification
state, that collects all copy number gains larger than 1, so some overestima-
tion might be expected. We obtained similar results in all other simulations
we considered. As for the transition matrix across CGH states, the estimates
appeared close to the truth [result reported in Cassese et al. (2014)].
4.3. Comparison with single stage approaches. We compare the results
based on our unified method, which performs simultaneous CNV detection
and selection of significant associations, to single stage approaches that focus
solely on CNV detection or solely on association analysis using the raw
measurements.
Using the CNV detection method of Guha, Li and Neuberg (2008), which
analyzes each sample separately, and specifying the same prior settings as
our model, there were, respectively, 2695 and 8349 misclassified CNV calls
for the two scenarios with σε = 0.1 (instead of 78 and 62 as reported for the
independent case in Table 3). This result demonstrates that the integration
of multiple samples and the joint modeling of gene expression data offer
improved estimation of copy number states.
We also looked into the performance of Bayesian variable selection in a
regression model where the predictors are the raw continuous CGH measure-
ments, therefore ignoring the inference of the latent copy number states. For
the prior on the variable selection indicators, since the copy number states
were not estimated, we cannot use prior model (5). Instead, we assumed the
independent prior rgm ∼ Bern(pi1) and set pi1 = 0.001. For σε = 0.1, using
Table 3
Simulated scenarios 1 and 2: Results on ξ as number of misclassified copy number states,
for the dependent prior model (8) and various values of α
# Miscl.
(percent) α= 5 α= 10 α= 20 α= 30 α= 40 α= 50 α= 100 α= ∞
Scenario 1 179 162 78 78 77 74 74 78
σε = 0.1 (0.179%) (0.162%) (0.078%) (0.078%) (0.077%) (0.074%) (0.074%) (0.078%)
Scenario 1 68 71 70 69 76 68 72 73
σε = 0.5 (0.068%) (0.071%) (0.07%) (0.069%) (0.076%) (0.068%) (0.072%) (0.073%)
Scenario 2 51 58 62 53 60 61 60 62
σε = 0.1 (0.051%) (0.058%) (0.062%) (0.053%) (0.06%) (0.061%) (0.06%) (0.062%)
Scenario 2 60 59 60 55 60 53 53 54
σε = 0.5 (0.06%) (0.059%) (0.06%) (0.055%) (0.06%) (0.053%) (0.053%) (0.054%)
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an FRD threshold of 0.05, we obtained specificity = 1 and sensitivity = 0.7
in the first simulated scenario and specificity = 1 and sensitivity = 0.2 in
the second scenario. In both cases the performance of the competing model
worse than to that of our model with the independent prior (see Table 2).
In particular, in the second scenario the model with the dependent prior
outperforms both the model with the independent prior and the competing
model that uses the raw continuous CGH measurements.
5. Case study on human cancer cell lines. We applied our model to the
analysis of the NCI-60 cell line panel, which consists of 60 human cancer
cell lines derived from a diverse set of tissues (brain, bone marrow, breast,
colon, kidney, lung, ovary, prostate and skin). We downloaded the normal-
ized aCGH Agilent 44K data and the Affymetrix HG-U133A RMA gene
expressions using CellMiner (discover.nci.nih.gov/cellminer). In the current
analysis, we excluded cell line 40 from the data set, since no gene expression
measurements were available in the repository. We imputed the remaining
missing values using the k-nearest neighbor algorithm with k = 5.
In performing our analysis we employed pathway-based scores of the gene
expression data. This strategy helped us to reduce the dependence between
the outcome variables in model (2) and also to achieve a dimension reduction
of the model space. Methods that employ pathway-based scores of gene
expression data have become quite popular in genomics; see, for example,
Su, Yoon and Dougherty (2009), Ovacik et al. (2010), Chen, Wang and
Ishwaran (2010), Drier, Sheffer and Domany (2013), among others. More
precisely, we considered the genes that map to each one of the 186 KEGG
pathways, using the software Compadre [see Rodriguez et al. (2012)]. Then,
for each pathway, we applied principal component analysis (PCA) to the
gene expression data and selected the components that explained at least
80% of the variability. This procedure led us to the selection of G = 3195
pathway components, which we used as response variables in model (2).
Furthermore, we considered the 1521 CGH probes mapping to chromosome 8
and selected those that showed variability across tissue types via an ANOVA
test with multiplicity correction. This resulted in a set of M = 89 CHG
predictors.
For model fitting, we used hyperparameter settings similar to those used
in the simulation scenarios described in Section 4. We ran 100,000 iterations
with a burn-in of 50,000, setting pR = 0.1, pξ = 0.3 and pMC = 0.9 in the
MH proposals. As suggested by the results of the simulations, we set α to
a relatively small value, that is, α= 25. For comparisons, we also looked at
the case α→∞ (i.e., the independent prior). As in the simulation study, we
assessed convergence by inspecting the MCMC sample traces for all param-
eters. Moreover, we applied the Geweke diagnostic test for the equality of
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Fig. 7. Case study: Heatmaps of PPIs of pathway-CNV associations using the dependent
prior with α= 25 (a) and the independent prior (b).
the means and the Heidelberger and Welch test on the stationarity of the
distribution to determine a suitable burn-in.
We ranked the marginal PPIs of the elements of R in order to identify the
most significant associations. Figure 7(a) shows a heatmap of the pathway-
CNV associations with highest PPI for the case α = 25 (roughly the top
100 associations, which correspond to a threshold of 0.07 on the PPIs).
Figure 7(b) shows the same selection for the independent prior. Notice that
the latter heatmap is more sparse. In addition, the heatmap for α= 25 shows
a stronger tendency to include groups of adjacent CGH probes as significant
for the same pathway component, which is coherent with how we built our
prior probability model.
As for inference on the copy number states, the estimates of the state spe-
cific means and variances were [−0.6419,−0.0105,0.49,1.0236] and [0.2059,
0.08115,0.1287,0.27138], respectively, which are consistent with the theoret-
ical values. Furthermore, the estimated transition matrix well captured the
state persistence of the CGHs (results not shown). We also notice that the
first and the last value of the vector of estimated variances are larger than
those corresponding to neutral and single gain states. This is what we would
expect, since the first and the last class correspond to multiple copy number
losses and gains, respectively. Finally, Figure 8 shows the estimated frequen-
cies of gains (single and multiple) and losses plotted along the samples for
each of the 89 CGH probes considered for analysis.
5.1. Biological interpretation of our findings. Our results identify poten-
tial links between genomic mutations, in the form of CNVs, and the tran-
scriptional activity of target pathways. In this section we explore the biolog-
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Fig. 8. Case study: Proportion of estimated gains and losses among the 59 samples for
the 89 CGH probes considered.
ical significance of the identified associations and assess whether they can
be used to generate biologically relevant hypotheses. Figure 9 is a schematic
representation of the conceptual relationships between genes linked to CGHs
for a set of 4 target pathway components. The 4 pathway components were
selected as those with the highest numbers of associations in Figure 7. For
each of the 4 components we report the top 20% of the genes with highest PC
loadings [subplots (A), (B), (C), (D), with bars representing the PC load-
ing values] as those with highest expression variability. Selected genes with
CNVs are also listed below the pathway names. Finally, dashed lines point at
genes with CNVs that overlap across selected pathways. These results iden-
tify two main molecular pathway blocks. The first [Figure 9(A)] represents
the connection between six genetic mutations with Arginine metabolism.
The second [Figure 9(B), (C), (D)] represents a partially overlapping set of
18 genomic mutations and the expression of genes involved in Glycosylphos-
phatidylinositol (GPI) anchor metabolism and Porphyrin metabolism.
There is strong evidence linking Arginine metabolism to cancer in the lit-
erature. For example, arginine metyiltransferases are key enzymes in mod-
ulating DNA methylation, a primary mechanism in neoplastic transforma-
tion [Yang and Bedford (2013)]. A connection between Arginine metabolism
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Fig. 9. Case study: Schematic representation of selected associations, showing the se-
lected genes with CNVs and the transcriptional predicted target genes (top 20% of the
absolute value of the PC loadings). Bars represent the PC loading values. Dashed lines
point at genes with CNVs that overlap across pathways.
and suppressor cells in cancer has also been proposed [Raber, Ochoa and
Rodr´ıguez (2012)]. Our results therefore suggest that the expression of a
number of enzymes involved in Arginine metabolism may be linked to spe-
cific mutations. Interestingly, several of these mutations are known cancer
genes. For example, it has been shown that mutations in Nucleoplasmin 2
(NPM2), a core histone chaperone involved in chromatin reprogramming, are
associated to increase resistance in a cancer cell line [Dalenc et al. (2012)].
In the supplementary material [Cassese et al. (2014)] we report details of
the functions of other mutations linked to the target pathways we have
identified.
Our results also identify a partially overlapping set of mutations linked to
GPI-anchor metabolism and Porphyrin metabolism [Figure 9(B), (C), (D)].
Similar to the Arginine metabolism, over-expression of several enzymes in
the GPI-anchor metabolism has been shown to induce tumorigenesis and
invasion in human breast cancer [Wu et al. (2006)]. On the other hand, no
direct link between the expression of Porphyrin metabolism genes and cancer
has been reported, although there is evidence that increased porphyrins
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may be a parallel disease in liver cancer models [Kaczynski, Hansson and
Wallerstedt (2009)].
Having identified possible relationships between genomic mutations and
target functional pathways, we wondered whether these might be also linked
to already known regulators involved in cancer. To test this hypothesis, we
looked at whether the lists of genes identified either as genetic mutations or
target genes are enriched for targets of known regulators. More specifically,
we searched for putative (directed or indirect) upstream regulators of all
genes involved in the Arginine, GPI-anchor and Porphyrin metabolisms as
well as putative upstream regulators of the genes with CNVs selected by
the model. We searched a database of known targets of transcription factors
and other regulators (www.ingenuity.com) and used a Fisher’s exact test
to assess whether there was a statistically significant overlap between the
genes in our lists and the genes regulated by each regulator in the database.
In this analysis we used a high stringency threshold (p < 10−6) to define
putative regulators. Figure 10 shows our findings. All 4 putative upstream
regulators identified at the high stringency threshold were genes known to be
of primary importance in cancer biology. These were the well-known onco-
genes MYC and p53, the Peroxisome proliferator-activated receptor PPAR
[Belfiore, Genua and Malaguarnera (2009)] and the reactive oxygen species
scavenger Superoxide dismutase SOD1 [Somwar et al. (2011) and Noor, Mit-
tal and Iqbal (2002)]. We found that genes connected to these regulators
were primarily representing enzymes involved in Arginine metabolism (76%
of the total targets, 35/46) representing 50% (35/72) of the genes in that
pathway. Of these, 6 represented genes within the top 20% PC loadings [Fig-
ure 9(A)]. Eight genes connected to the 4 identified regulators (17% of the
total targets) were representing enzymes in the Porphyrin metabolism path-
way (representing 17% of the total pathway genes, 8/46). Interestingly, no
genes with CNVs selected in the Arginine metabolism model were linked to
the 4 regulators. Instead, 2 of the 3 genes with CNVs included in Figure 10
were in the Porphyrin metabolism pathway block and 1 in the GPI-anchor
metabolism. Overall, these findings support the hypothesis that the associ-
ations we have identified represent genes highly implicated in cancer.
6. Discussion. In this paper we have developed a hierarchical Bayesian
modeling framework for the integration of high-throughput data from dif-
ferent sources. We have focused in particular on gene expression levels and
CGH array measurements, collected on the same subjects. Our modeling
framework has several innovative features. First, it allows the identification
of the joint effects of multiple CNVs on mRNA transcript abundance. Sec-
ond, it reduces the bias that arises when ignoring the uncertainty in the
CNV estimation process (i.e., using copy number calls as if they were the
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Fig. 10. Case study: Potential upstream regulators of the selected genes with CNVs and
target genes. The plot shows the top 4 most likely regulators (p < 10−7), that is, PPAR,
the oncogenes MYC and p53 and the ROS scavenger SOD1. These are upstream to many
of the Arginine metabolism genes (represented by the red circles), including a large number
of those in the top 20% of the PC loadings (filled red circles). Some Porphyrin metabolism
transcriptional targets are also included (green circles and filled green circles). Further-
more, 3 of the selected genes with CNVs are linked to the 4 regulators (yellow filled green
and red circles).
true states), by allowing the simultaneous inference of CNVs and their as-
sociation to gene expression. We have shown in simulations that noise in
the raw measurements leads to the detection of spurious associations and
also that it is advantageous to incorporate the estimation of copy numbers
into the analysis, as this reduces the detection of false positive associations.
Findings from an analysis we have conducted on data from 60 cancer cell
lines support the hypothesis that the model we have developed has the po-
tential to identify important linkages between gene expression and CNVs.
The data set we have considered spans a large spectrum of tissues and cancer
types. It is expected that the detection power of our approach will be higher
with more defined patient populations. These studies will require dedicated
clinical studies.
BAYESIAN MODELING FOR GENE-CNV ASSOCIATION AND INFERENCE 25
Our model aims to identify contiguous regions of DNA aberration that
jointly affect the expression of a gene. To accomplish this, we have specified
selection priors that cleverly account for spatial dependence across DNA
segments. This prior model depends on a parameter, α, that plays an im-
portant role in capturing the dependence structure. We investigated the
option of putting a prior distribution on this parameter. However, with a
Gamma prior, for example, and a Metropolis–Hastings step to sample α,
the data only have an indirect effect on the MH acceptance ratio, via the
definition of s(m−1)m and the values of rgm, and the MH ratio is dominated
by the prior probability of rgm. As seen in Figure 3, the prior probability
of inclusion/exclusion increases if the neighbors are included/excluded, and
this effect is particularly dramatic for the prior probability of inclusion under
lower values of α. This causes the sampler to move to regions of the posterior
characterized by higher dependence between contiguous states, accepting a
move every time a smaller value of α is proposed. Such behavior could be
prevented by introducing a second parameter in the prior, in order to penal-
ize for large numbers of included links. The construction of such prior will
need further investigation on our part. We find the single-parameter prior
model we have proposed here rather intuitive and easy to specify. In our
simulations we have found values of α in the range α= [20,50] to work well,
leading to a good balance between the number of FN and FP. Results shown
in Table 2, in fact, are clearly robust to the choice of α in this range. Values
lower than 20 lead to a steady increase in the number of included links, while
values higher than 50 result in priors closer and closer to the independent
model. Moreover, for all the simulated examples and all α values in the sug-
gested range, the top 15 links identified with highest posterior probability
of inclusion are all true associations. In the case study, as typical with high-
throughput genomic data, where there is a high degree of multicollinearity
among the covariates, different MCMC runs might pick different subsets of
the predictors, as variables that are highly correlated act as proxies for each
other and would be picked by different chains. This behavior is, in general,
independent of the chosen specification of the α parameter.
In the case study we have applied a heavy filtering of the CGH probes.
Filtering and/or dimension reduction methods are often used in applications
of HMM models to CGH data; see, for instance, Du et al. (2010), Fox et al.
(2011), Guha, Li and Neuberg (2008), Costa et al. (2013). Caution is neces-
sary when applying such preprocessing steps, as they may result in large gaps
between probes, thus decreasing the dependence between adjacent probes
and/or inducing heterogeneity in the gap size. In order to assess whether
the HMM approach is indeed beneficial, we looked at results on the estima-
tion of ξ without the HMM formulation. For this we considered the counts
across the four different states as arising from a multinomial distribution and
assumed a Dirichlet hyperprior. As we did with the HMM setting, we set
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all hyperparameters of the Dirichlet to 1. We obtained state specific means
[−0.25,−0.03,0.14,3.54] and variance estimates [0.41,0.19,0.41,0.78]. The
HMM formulation instead resulted in estimated means that were closer to
the theoretical values as well as in lower variance estimates (results reported
on page 25). In addition, looking at the distributions of the estimated states,
the HMM approach resulted in a larger number of neutral states, whereas
the no-HMM model classified many of these as single copy number gains.
Given the biological evidence that neutral states should be more common,
we believe this suggests that the performance of the HMM formulation is
superior despite the heavy filtering applied to the data. A possible improve-
ment of our HMM model could be to incorporate the distances between
adjacent probes in the evaluation of the transition matrix, to account for
possible heterogeneity in the gap size, as done in Colella et al. (2007) and
Wang et al. (2007).
Other improvements of our model include the use of indicator variables
to model the CNV effects, in order to relax the assumption of a linear as-
sociation of the ξ categories on the Y s. This would lead to a 2-fold increase
(with four categories) in the dimension of the matrix of predictors, therefore
increasing computational times. Finally, although we have focused on array
CGH data, the proposed method can easily be extended to CNV detection
using genome-wide SNP arrays. This can be done by modifying the emission
distributions in the HMM and modeling the log-intensity ratios in equation
(3) as a mixture of uniform and normal distributions, as in Wang et al.
(2007) and Colella et al. (2007).
SUPPLEMENTARY MATERIAL
Supplement to “A hierarchical Bayesian model for inference of copy num-
ber variants and their association to gene expression”
(DOI: 10.1214/13-AOAS705SUPP; .pdf). Description of the MCMC steps
and additional results on the case study.
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